Gyros Protein Technologies introduces Gyrolab HEK293 HCP Type SN and Type CL Kit Reagents to support biotherapeutic development

Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers, today announced the introduction of its Gyrolab® HEK293 HCP Type SN Kit Reagents and Gyrolab…

Continue ReadingGyros Protein Technologies introduces Gyrolab HEK293 HCP Type SN and Type CL Kit Reagents to support biotherapeutic development

SAB BIO announces positive topline Phase 1 clinical results with potentially disease-modifying T1D therapy SAB-142

SAB BIO, (“SAB BIO”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes…

Continue ReadingSAB BIO announces positive topline Phase 1 clinical results with potentially disease-modifying T1D therapy SAB-142